NGEN NervGen Pharma Corp.
Financings ·
NervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units.
NervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | C$13.9 million | C$15.8 million |
| Net income (loss) | -C$44.1 million | -C$24.3 million |
| Cash from operations | -C$19.5 million | -C$16.8 million |
| Cash and equivalents | C$22.1 million | C$17.3 million |
Our latest story on this, dated Aug 13, 2026: "NervGen reports C$86,789,698 cash after May 2026 public offering". The story links the filing or release it is based on. Read the story.
NervGen Pharma Corp. trades under the ticker NGEN on NASDAQ.
NervGen Pharma Corp. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9UA; LS:A2QP3D; LSX:A2QP3D.
The SEC Central Index Key (CIK) for NervGen Pharma Corp. is 1751912. Its filings are on SEC EDGAR.
Our directory records NervGen Pharma Corp. under Canada.
Our directory classifies NervGen Pharma Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for NervGen Pharma Corp. is CA64082X2032.
aibio.space lists NervGen Pharma Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
Our latest story on NervGen Pharma, dated Aug 13, 2026: "NervGen reports C$86,789,698 cash after May 2026 public offering". NervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units. Source.
From our story of Aug 13, 2026: The going concern note says management forecasts that existing working capital will be sufficient for 12 months from the date the statements were issued. Source.
From our story of May 18, 2026: It had cash and investments of $16.6 million at March 31, 2026. Source.
Our latest listing story, dated May 18, 2026: "NervGen reports $16.6 million cash and investments after Nasdaq listing". NervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding. Source.
SEC records list NervGen Pharma Corp.'s filer category as: <br>Emerging growth company.
SEC records list its business address as 112-970 BURRARD STREET, VANCOUVER, V6Z 2R4.
NervGen Pharma Corp.'s fiscal year ends on December 31, per SEC records.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio